Summary: Metabolic syndrome (MS) is the co-occurrence of cardiometabolic factors leading to worsening of cardiovascular risk. One of them is atherogenic dyslipidemia defined as non-HDL cholesterol level ≥130 mg/dl. A patient diagnosed with metabolic syndrome is at least a high-risk cardiovascular patient. Treatment of atherogenic dyslipidemia should involve lowering LDL cholesterol levels to recommended values through statin therapy in monotherapy or in combination with ezetimibe. It should be remembered that patients with MS still have a residual risk, defined by non-HDL cholesterol levels. Therefore, in this group of patients, the addition of a fibrate to statin and ezetimibe treatment may be considered. Such treatment will lower the concentration of non-HDL cholesterol and thus may reduce cardiovascular risk. It should also be emphasized that, as in any treatment of lipid disorders, broad lifestyle modification should always be recommended as the basis of therapy in patients with MS.